In essence, PD-1/PD-L1 inhibition is set to expand its role in oncology, with scientific advances, practical strategies, and novel clinical trials contributing to its evolution, thereby advancing the paradigm of cancer care and fortifying the hope for improved patient prognoses. Here, CD274 is linked to cancer.